← Leaderboards
Margaret Rosenfeld
University Of Washington
$6,120,159
Attributed
$9,150,152
Total exposure
13
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,150,152 · 13
By mechanism
U01$5,753,607 · 2
U54$2,118,570 · 1
K23$538,275 · 1
R21$381,588 · 1
R41$306,380 · 1
M01$51,732 · 7
Top collaborators
- Donald Leslie Chi8 shared
- Stephanie Duggins Davis4 shared
- Susan A Stoner1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Donald Leslie Chi$10,851,003
- Charlotte Wood Lewis$1,658,638
- Kathleen Jessica Ramos$3,387,316
- Timothy A Derouen$29,069,189
- Lori J Leibold$13,140,233
Others in their field
Top investigators on “Cystic Fibrosis”
- John F Engelhardt · University Of Iowa$42,933,706
- Michael R Knowles · University Of North Carolina Chapel Hill$30,250,682
- David A Stoltz · University Of Iowa$25,455,359
- Joseph Zabner · University Of Iowa$25,382,103
- Paul B McCray · University Of Iowa$25,146,293
- Richard C Boucher · University Of North Carolina Chapel Hill$24,890,955
Research focus
Cystic FibrosisChronicClinical TrialsMucociliary ClearanceRespiratoryEnrollmentQuality Of LifeObstructive Lung DiseasesLung DiseasesRespiratory HealthLungVisitImpairmentAntibioticsPulmonary FunctionCystic Fibrosis PatientsCaringCohortSymptomsMeasurementPulmonary Function Test/Forced Expiratory Volume 1SputumCessation Of LifeClinical Research
Grant awards (38)
Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions$636,485
U01 · FY2025 · DE
Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions$692,010
U01 · FY2024 · DE
Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions$31,037
U01 · FY2024 · DE
Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions$736,031
U01 · FY2023 · DE
Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia$412,371
U54 · FY2023 · HL · contact PI
Clinical Trial Readiness - Primary Ciliary Dyskinesia (CTR-PCD)$169,427
R21 · FY2023 · TR · contact PI
Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions$77,951
U01 · FY2023 · DE
Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions$733,499
U01 · FY2022 · DE
Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia$421,096
U54 · FY2022 · HL · contact PI
Clinical Trial Readiness - Primary Ciliary Dyskinesia (CTR-PCD)$212,161
R21 · FY2022 · TR · contact PI
Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions.$24,948
U01 · FY2022 · DE
Understanding Oral Diseases in Cystic Fibrosis to Develop Tailored Preventive Dental Interventions$795,360
U01 · FY2021 · DE
Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia$423,706
U54 · FY2021 · HL · contact PI
Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia$428,769
U54 · FY2020 · HL · contact PI
Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia$432,628
U54 · FY2019 · HL · contact PI
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) - CCC - Lead Application$443,348
U01 · FY2011 · HL · contact PI
CF-ePRO: Electronic Self- and Parent-Reported Patient Outcomes in Cystic Fibrosis$306,380
R41 · FY2011 · HL
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) - CCC - Lead Application$517,638
U01 · FY2010 · HL · contact PI
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) - CCC - Lead Application$533,626
U01 · FY2009 · HL · contact PI
Infant Study of Inhaled Saline in Cystic Fibrosis (ISIS) - CCC - Lead Application$531,674
U01 · FY2008 · HL · contact PI
LUNG FUNCTION MEASURES IN PRESCHOOL CHILDREN WITH CYSTIC FIBROSIS$991
M01 · FY2007 · RR · contact PI
RARE GENETIC DISORDERS OF THE AIRWAYS: DEVELOPMENT OF NOVEL SCREENING$382
M01 · FY2007 · RR · contact PI
EVALUATION OF PULMONARY FUNCTION TESTS FOR OUTCOME MEASURES IN INFANT WITH CF$76
M01 · FY2007 · RR · contact PI
TOBRAMYCIN ACCUMULATION IN THE RESPIRATORY SECRETIONS OF CF PATIENTS WITH REPE$5,788
M01 · FY2006 · RR · contact PI
EVALUATION OF PULMONARY FUNCTION TESTS FROM RAISED LUNG VOLUMES AS OUTCOME MEAS$4,962
M01 · FY2006 · RR · contact PI
EVALUATION OF PULMONARY FUNCTION TESTS AS OUTCOME MEASURES IN INFANTS WITH CF$12,837
M01 · FY2005 · RR
TOBRAMYCIN ACCUMULATION IN CF PATIENTS: PILOT STUDY$5,706
M01 · FY2005 · RR
PILOT STUDY:TOBRAMYCIN ACCUMULATION IN THE RESPIRATORY SECRETIONS OF CF PATIENTS$2,852
M01 · FY2005 · RR
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$112,271
K23 · FY2004 · RR
Evaluation of pulmonary function tests from raised lung$4,771
M01 · FY2004 · RR
Tobramycin accumulation in the respiratory secretions of CF patients with repe$4,771
M01 · FY2004 · RR
Tobramycin accumulation in CF patients: Pilot study$868
M01 · FY2004 · RR
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$109,787
K23 · FY2003 · RR
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$107,376
K23 · FY2002 · RR
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$105,041
K23 · FY2001 · RR
MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW$103,800
K23 · FY2000 · RR
SAFETY OF AEROSOLIZED TOBRAMYCIN IN YOUNG CHILDREN W/ CYSTIC FIBROSIS$3,864
M01 · FY2000 · RR
SAFETY OF AEROSOLIZED TOBRAMYCIN IN YOUNG CHILDREN W/ CYSTIC FIBROSIS$3,864
M01 · FY2000 · RR